# Anti-Estrogen Therapy for Hereditary Hemorrhagic Telangiectasia A Double-Blind Placebo-Controlled Clinical Trial

> **NCT00375622** · PHASE2 · COMPLETED · sponsor: **Rabin Medical Center** · enrollment: 60 (—)

## Conditions studied

- Hereditary Hemorrhagic Telangiectasia

## Interventions

- **DRUG:** Tamoxifen

## Key facts

- **NCT ID:** NCT00375622
- **Lead sponsor:** Rabin Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** —
- **Final completion:** 2006-06
- **Target enrollment:** 60 (—)
- **Last updated:** 2006-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00375622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00375622, "Anti-Estrogen Therapy for Hereditary Hemorrhagic Telangiectasia A Double-Blind Placebo-Controlled Clinical Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00375622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*